Cancer Genomics

Hereditary Cancer Detection

What is Cancer Genomics (CGx)?

The study of cancer genomes has revealed abnormalities in genes that drive the development and growth of many types of cancer. This knowledge has improved our understanding of the biology of cancer and led to new methods of diagnosing and treating the disease.

How will RM's CGx testing benefit patients?

RM's genetic testing can help determine if one is at an increased risk of developing hereditary cancer. In addition, our CGx test helps guide physicians to pursue preventative measures, which may lead to early detection and treatment of the condition. Accuracy of results is crucial.

Who is at an increased risk for hereditary cancer?

If you or your family have a history of any of the following:

- An individual that has more than one cancer
- An individual that has multiple close family members with a cancer diagnosis under the age of fifty
- An individual that has three or more close family members with different types of cancer
- An individual that has had family that has previously had cancer genetic testing and mutations were identified

Some people are genetically more likely to develop certain types of cancers, and cancer genomics helps to uncover these risks. After receiving the patient’s DNA sample and carrying out a thorough test, we then compile the results into an in-depth yet easy to understand report detailing all the information you need to know. Using the most advanced sequencing technology on the market, we provide incredibly accurate results which physicians can then use to create a personalized therapy based on your genome.

Why trust RM with your cancer genomics testing?

RM uses the latest Next-Generation Sequencing (NGS) technology to analyze patient samples in a rapid and accurate approach. All genetic scientists at RM labs are highly trained and handle testing with the utmost care; our genetic specialists are always available for in-depth consultations. RM's CGx reports are easy to read and provide you with clinically significant data based on the most recent medical innovations.

Cancer Statistics

Click here
Statistics
  • APC - Colorectal, central nervous system, thyroid, liver, duodenal, pancreatic
  • ATM - Breast, pancreatic
  • NBN - Breast, prostate, possibly ovarian
  • BRCA1, BRCA2 - Breast, ovarian, prostate, pancreatic, male breast
  • BRIP1, RAD51C, 
    RAD51D - Breast, ovarian
  • BMPR1A, SMAD4 - Stomach, colorectal, pancreatic
  • CDH1 - Breast, colorectal, gastric
  • CDK4 - Melanoma
  • CDKN2A - Melanoma, pancreatic
  • CHEK2 - Breast, colorectal
  • FH - Kidney, leiomyomas
  • FLCN - Kidney
  • MAX - Pheochromocytoma
  • MLH1, MSH2, 
    MSH6, PMS2,
    EPCAM - Ovarian, colorectal, uterine, stomach, small bowel, hepatobiliary, brain, pancreatic, sebaceous, urinary tract
  • MUTYH - Breast, colorectal
  • NF1 - Optic glioma, gastrointestinal stromal tumor,
    paraganglioma/pheochromocytoma, neurofibromas, breast, Central
    nervous system
  • PALB2 - Breast, pancreatic
  • PTEN - Breast, uterine, thyroid, colorectal, kidney
  • RET - Thyroid (medullary), Pheochromocytoma
  • SDHAF2, SDHB, 
    SDHC, SDHD - Kidney, paraganglioma/pheochromocytoma, gastrointestinal stromal tumor
  • TSC1, TSC2 - Kidney, cardiac rhabdomyomas, central nervous system
  • STK11 - Colorectal, small bowel, pancreatic, breast, ovarian
  • TMEM127 - Paraganglioma/pheochromocytoma
  • TP53 -Brain, leukemia, breast, sarcoma, adrenocortical, gastrointestinal,
    genitourinary

    VHL - Kidney, pheochromocytoma, central nervous system

If you or your family have a history of any of the following, then you could be at an increased risk of a hereditary cancer:

One person suffering from multiple types of cancer

Several close relatives under 50 being diagnosed with cancer

A relative who previously had genetic mutations identified through cancer genomics


Benefits for the Ordering Physician

If standard treatments have failed, such as chemotherapy, cancer patients often need more targeted, personalized treatment plans. The genomic tests available at our uncover patientspecific variants that predict response to treatment. Some of the specific benefits and advantages of the tests include:

Genomic profiling to enable more personalized patient care and treatment efficient, cost-effective and sensitive somatic variant analysis

Advantages of our Next Generation Sequencing (NGS) assays

Additional predictive targets for improved and more immediate clinical utility of tests

Wide range of variant types detected, including substitutions, insertions, deletions, and multiple structural rearrangements

Comprehensive reports with easy-to-understand result summaries and interpretations

Cancer genomics reports are easy to read and provide you with clinically significant data based on the most recent medical literature. Trust our cancer genomics testing services for your patients.

CONTACT

135 E. 57th St., 14th Floor
New York, NY 10022

(877) RM GENETICS
(877) 764-3638

info@rmgenetics.com

ABOUT RM GENETICS

At RM Genetics, we strive to work with health providers and facilities to help them offer personalized medical care to their patients and residents. We provide complete program management and support that allows healthcare providers the ability to offer optimal patient care with no inconveniences or added operational requirements. Our Pharmacogenomic testing programs are customized to the patient and resident treatment types and are covered by Medicare and other Health Insurance providers.